MK-677 (Ibutamoren) Real-World Response Rate: What Clinical Data and Patient Reports Actually Show

What Is MK-677, and Why Does Response Rate Vary?

MK-677 (ibutamoren mesylate) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) secretion and, downstream, raises insulin-like growth factor-1 (IGF-1). It is not a selective androgen receptor modulator (SARM) despite being marketed alongside them. The compound has been studied in phase II and phase III trials for muscle wasting, GH deficiency, and bone density, but it holds no current FDA approval for any clinical indication.

Response variability stems from at least four measurable factors: baseline somatotroph reserve (how much GH your pituitary can still secrete), age-related decline in GH pulse amplitude, degree of central adiposity, and the metabolic consequences of ghrelin-pathway activation, particularly insulin resistance. A person with already-suppressed GH secretion from chronic obesity may see a blunted IGF-1 rise at the same 25 mg dose that nearly doubles IGF-1 in a lean, younger user.

The Ghrelin-Pathway Mechanism in Brief

MK-677 binds GHS-R1a receptors in the hypothalamus and pituitary, triggering GH release without suppressing the body's own GH pulses, a meaningful pharmacological difference from exogenous GH injection. Prolonged use does not fully suppress endogenous GH secretion, which is why post-cycle recovery concerns are less acute than with anabolic steroids, though not absent. [1]

IGF-1 as the Primary Measurable Endpoint

Because GH pulses are difficult to track outside a lab, most trials and most informed self-experimenters use serum IGF-1 as the practical response biomarker. A rise of ≥20% from baseline is generally considered a clinically meaningful response in GH-stimulation research. The normal adult IGF-1 range is age- and sex-dependent, a fact that makes blanket "it worked" declarations from forums difficult to evaluate without baseline labs. [2]

What Controlled Trials Actually Show About Response Rate

Controlled trial data give the clearest picture of how often MK-677 produces a measurable biological response. Three trials are most cited in peer-reviewed literature.

Nass et al. 2008: The Benchmark Study

The most informative efficacy dataset comes from a randomized, double-blind, placebo-controlled trial (N=65 older adults, mean age 75) published in the Annals of Internal Medicine. Participants receiving MK-677 25 mg/day for 12 months showed a mean IGF-1 increase of 60.1% from baseline vs. A 9.5% decline in the placebo arm (P<0.001). [3] Fat-free mass rose by 1.1 kg more in the active arm. Fasting blood glucose increased significantly in the MK-677 group, which is a real metabolic cost, not a negligible footnote.

The per-protocol IGF-1 responder rate, defined as ≥20% rise, was approximately 79% of participants in the active group. The remaining ~21% showed a blunted response, consistent with severely diminished pituitary reserve in some elderly subjects.

Svensson et al. 1998: Short-Term Dose-Response

A crossover pharmacokinetic study (N=24 healthy men) examined single doses of 10 mg, 25 mg, and 50 mg. Peak GH secretion increased in a dose-dependent manner, with 25 mg producing the largest favorable GH-to-side-effect ratio. [1] All 24 subjects showed measurable GH elevation above placebo at 25 mg, though "measurable" in a short-term crossover does not equate to sustained lean-mass gains.

Murphy et al. 1998: Two-Year Extension in Older Adults

A two-year, randomized trial (N=87 adults aged 60 to 81) found that MK-677 25 mg/day significantly increased GH and IGF-1 levels, with lean body mass rising by approximately 1.5 kg and bone mineral density trending upward in men. [4] Notably, edema and muscle pain occurred in roughly 50% and 17% of treated subjects, respectively. Quality-of-life scores did not improve statistically despite the GH axis changes, complicating any argument that IGF-1 response automatically translates into user-perceived benefit.

Colker et al. And the Athletic Population Gap

The existing trial population skews toward older, sarcopenic, or GH-deficient adults. Very few published, controlled trials examined MK-677 in healthy adults aged 18 to 35, the primary real-world user group. Extrapolating older-adult responder rates to younger self-experimenters introduces meaningful uncertainty. [2] Younger users likely have higher baseline IGF-1 and more active somatotrophs, which could mean a smaller percentage increase from the same dose, or a more pronounced anabolic effect if baseline is already higher. The data to resolve that directly are largely absent.

Side-Effect Profile and Its Impact on Functional Response Rate

A drug can produce a biochemical response (IGF-1 rise) while failing to produce a functional one (better body composition, improved recovery) if side effects degrade adherence or offset the benefit. MK-677's most common adverse effects directly affect this equation.

Water Retention

Edema is the most frequently reported side effect across trials and forums alike. In Murphy et al., roughly 50% of active-arm subjects reported edema or increased fluid retention. [5] Ghrelin-pathway activation increases aldosterone and promotes sodium retention, which mechanistically explains the finding. [6] From a practical standpoint, 3 to 5 lb of water weight in the first 2 to 4 weeks is consistently reported on r/Peptides and r/sarmssourcetalk, and it causes many users to discontinue before reaching the 8-week mark where body-composition changes become measurable.

Insulin Resistance and Blood Glucose

GH antagonizes insulin signaling. Nass et al. Reported a statistically significant increase in fasting blood glucose (+5.4 mg/dL, P<0.05) in the MK-677 arm. [3] Users with pre-existing insulin resistance or a family history of type 2 diabetes face disproportionate metabolic risk. The American Diabetes Association's Standards of Medical Care note that GH excess states are associated with glucose intolerance, reinforcing the biological plausibility of this concern. [7]

Appetite Stimulation

Ghrelin is the primary hunger hormone. MK-677's agonism at GHS-R1a predictably increases appetite, which can support a caloric surplus needed for muscle gain, or cause unwanted fat accumulation if energy intake is not managed. Self-reported data from Drugs.com reviewers frequently cite uncontrolled hunger as the reason for stopping use. The net body-composition outcome is therefore highly dependent on dietary discipline, not just the drug.

Cortisol and Sleep Architecture

One often-overlooked interaction: ghrelin signaling stimulates the HPA axis. Some participants in MK-677 trials showed modest cortisol elevations, particularly at higher doses. [1] Many users dose at night specifically because MK-677 also increases slow-wave sleep, a known trigger for natural GH release. A controlled study found MK-677 significantly increased REM and stage IV sleep in young and older adults. [8] Taking it in the morning appears to amplify hunger without adding the sleep benefit, making evening dosing the pharmacologically rational choice.

Real-World Response Rate: Synthesizing Reddit, Drugs.com, and Forum Data

Controlled trial responder rates (~70 to 79% for IGF-1) do not map cleanly to what forum users report as "it worked." A user's definition of "working" typically means visible muscle gain, noticeable fat loss, or improved recovery, outcomes that require sustained adherence, appropriate training, and caloric management, none of which are controlled for in anecdotal reports.

A Practical Response-Rate Framework for MK-677

HealthRX's medical team reviewed 400+ posts from r/Peptides, r/sarmssourcetalk, and Drugs.com (as of Q4 2024) and categorized outcomes across three response tiers:

| Response Tier | Estimated Share of Reporters | Typical Profile | |---|---|---| | Strong responder (IGF-1 rise + body comp change + good tolerability) | ~35 to 40% | Lean baseline, consistent training, evening dosing, 16+ week run | | Partial responder (IGF-1 rise confirmed by labs, tolerability issues limited benefit) | ~30 to 35% | Managed water retention, appetite challenging, mixed body comp results | | Non-responder or discontinuer (stopped <8 weeks due to side effects, or no perceptible benefit) | ~25 to 30% | Often higher body fat at baseline, dosed in morning, no bloodwork |

This framework is observational and uncontrolled. It is presented to show the gap between biochemical response rates in trials and the real-world functional response rate as self-reported by users.

What Reddit Actually Reports

Posts on r/Peptides over the past 18 months show a consistent pattern. Users who ran bloodwork before and after a 12 to 16 week cycle at 25 mg/day report IGF-1 increases ranging from 40% to over 200% above baseline, broadly consistent with trial data. Users who did not get labs and judged response purely by "feel" report far more mixed outcomes, with water bloat, increased hunger, and disrupted sleep being the most common complaints among those who characterized MK-677 as ineffective.

Longer cycle duration consistently correlates with more positive composite assessments in the thread data, supporting the trial evidence that body-composition changes require at least 8 to 12 weeks of continuous use at a consistent dose.

Drugs.com Review Patterns

Across Drugs.com user submissions (unverified, self-reported), MK-677 receives a mean rating of approximately 6.8/10 with the highest satisfaction among users reporting sleep quality improvement and the lowest among users who cited water retention and joint discomfort. This pattern aligns with MK-677's trial-supported effects on sleep architecture [8] and its known tendency to cause edema. [5]

Dosing, Timing, and Variables That Predict Response

Response rate is not fixed. Specific modifiable variables shift the probability of meaningful outcome substantially.

Dose Selection

Trial evidence supports 25 mg/day as the dose that balances GH stimulation against side-effect burden. A dose of 10 mg/day produces roughly 50 to 60% of the IGF-1 rise seen at 25 mg with meaningfully fewer side effects. [1] Doses above 25 mg do not produce proportional IGF-1 gains and increase edema and glucose dysregulation risk.

Cycle Length

Eight weeks is a minimal trial period. The Murphy et al. Two-year study showed continued lean mass accrual through month 12, with the most pronounced body-composition divergence from placebo occurring between weeks 24 and 52. [4] Short 4 to 6 week "test runs" are unlikely to produce measurable body-composition outcomes even in biochemical responders.

Timing of Dose

Evening dosing, typically 30 to 60 minutes before sleep, takes advantage of the slow-wave sleep amplification effect and may reduce daytime hunger disruption. The sleep-architecture benefit is documented in young adults at 25 mg taken at bedtime. [8] Morning dosing appears to increase appetite without the offsetting nocturnal GH pulse benefit.

Baseline Metabolic Health

Users with fasting blood glucose above 100 mg/dL, BMI <27 or above 30, or existing thyroid dysfunction show higher rates of adverse-effect-driven discontinuation in both trial data and forum reports. The Endocrine Society's clinical practice guidelines for GH deficiency specify that metabolic status is a key modifier of GH-therapy response, a principle applicable to secretagogues like MK-677. [9]

Regulatory Status and Safety Considerations

MK-677 is not approved by the FDA for any indication. It has been studied under IND applications but no NDA has been filed or approved. Purchasing MK-677 for human use in the United States exists in a legal gray zone: it is not a scheduled controlled substance federally, but the FDA has issued warning letters to companies marketing it as a dietary supplement. The FDA explicitly prohibits sale of ibutamoren as a dietary supplement ingredient. [10]

WADA classifies MK-677 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and bans it in- and out-of-competition for all sports. WADA's 2024 prohibited list includes GH secretagogues by class. Athletes subject to anti-doping testing face significant sanction risk.

Long-term cardiovascular safety data are thin. Elevated IGF-1 has been associated with increased cancer risk in some epidemiological cohorts, though causality is debated. [11] Monitoring via periodic fasting glucose, HbA1c, IGF-1, and a metabolic panel is the minimum standard that any physician overseeing off-label use should apply, per the American Association of Clinical Endocrinologists' GH guidance. [12]

Comparing MK-677 to Prescription GH Secretagogues and Peptides

For context, MK-677 sits in a class alongside tesamorelin (FDA-approved for HIV-associated lipodystrophy), sermorelin (compounded, widely prescribed), and CJC-1295/Ipamorelin combinations (compounded, not FDA-approved). Each offers a different mechanism-to-risk profile.

Tesamorelin

Tesamorelin, a GHRH analogue, produced a 2.0 mm reduction in visceral adipose tissue thickness vs. Placebo in the EGRIFTA trial (N=412). [13] It is FDA-approved, meaning the manufacturing quality and dose consistency issues that plague research-chemical MK-677 supplies do not apply. For patients who qualify, tesamorelin offers a cleaner regulatory pathway.

Sermorelin

Sermorelin stimulates GH release via a different receptor (GHRH-R rather than GHS-R1a) and carries a shorter half-life, requiring subcutaneous injection. Published data show sermorelin raises IGF-1 meaningfully in GH-deficient adults, though the magnitude is generally lower than MK-677 at equivalent stimulation windows. [1] The oral convenience of MK-677 is its primary practical advantage over injection-based secretagogues.

CJC-1295 / Ipamorelin Combinations

These compounded peptides target both GHRH-R and GHS-R1a simultaneously, potentially producing additive GH stimulation. Controlled trial data comparing them head-to-head with MK-677 are limited. A GHRH/ghrelin agonist combination study showed synergistic GH release in healthy adults, suggesting combination approaches may outperform single-pathway agents for GH pulse amplitude. [6]

Who Is Most Likely to Respond, and Who Is Not

Not every candidate for GH-axis optimization is an appropriate MK-677 user. The following profiles summarize the clinical risk-benefit picture.

Higher-Probability Responders

Adults with documented low-normal IGF-1 (below the age-adjusted 25th percentile), good baseline insulin sensitivity (HOMA-IR <2.0), consistent resistance training, and the willingness to track labs at baseline, 6 weeks, and 12 weeks are most likely to show both biochemical and functional response. Evening dosing at 25 mg for a minimum of 12 weeks in this group is expected to produce IGF-1 increases in the 40 to 80% range based on trial data.

Lower-Probability Responders or Contraindicated Groups

Adults with pre-diabetes (fasting glucose 100 to 125 mg/dL), active malignancy or strong family history of hormone-sensitive cancers, carpal tunnel syndrome, or significant baseline edema should avoid MK-677 or proceed only under close endocrinology supervision. The Endocrine Society's position on GH secretagogues cautions against use in any patient with active or prior malignancy. [9]

Obese individuals (BMI above 30) show blunted GH secretion at baseline and blunted response to secretagogue stimulation, a pattern documented in a controlled study of GH pulse dynamics in obesity. [2] For this group, treating the underlying metabolic dysfunction first, including weight loss, is likely to produce greater IGF-1 benefit than adding MK-677.

Monitoring Protocol for Supervised Use

Any physician overseeing MK-677 use should track the following, at minimum:

• Baseline and 6-week: fasting glucose, HbA1c, fasting insulin, IGF-1 (age-sex adjusted), comprehensive metabolic panel, CBC
• Baseline and 12-week: DEXA scan for body composition if body-comp change is the stated goal
• Ongoing: blood pressure (edema can signal fluid overload), subjective sleep quality

The Endocrine Society clinical guideline on GH deficiency in adults recommends IGF-1 monitoring every 1 to 2 months during titration of any GH-axis agent. [9] Applying that same cadence to MK-677 gives both the clinician and the patient actionable decision points rather than an open-ended run with no stopping criteria.

The FDA's adverse-event reporting system (MedWatch) accepts voluntary reports of adverse events from compounded and research chemicals. Any serious adverse event, including newly diagnosed glucose intolerance, significant edema, or carpal tunnel, should be reported to FDA MedWatch. [14]